+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 19Years +
All Genders
ID06555432

Study of LIVTENCITY Maribavir for Treating Cytomegalovirus Infection After Transplant in Adults in South Korea

Led by Takeda · Updated on 2025-11-18

168

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Cytomegalovirus CMV is a common virus that can cause serious illness, especially in people with weakened immune systems after a transplant. Researchers are evaluating the safety and effectiveness of LIVTENCITY Maribavir, a medicine approved in South Korea for treating CMV infection in adults after transplantation. This observational study aims to learn how LIVTENCITY works in routine clinical practice for these patients. Participants who have CMV infection or disease after a transplant and are resistant or refractory to one or more prior therapies such as ganciclovir, valganciclovir, foscarnet, or cidofovir will be treated with LIVTENCITY tablets as decided by their doctors. The study will follow participants for up to 20 weeks while they receive treatment according to approved labeling. During this approximately 5-month period, participant information will be collected without fixed hospital visit requirements, though visiting the study doctor about six times is recommended. Researchers will monitor adverse events, drug reactions, and CMV viral clearance through PCR tests at weeks 2, 8, and the end of treatment. They will also assess symptom control and collect safety data throughout the study.

CONDITIONS

Brief Title

A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea

Research Team

T

Takeda Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here